Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.72 |
| ▸ | CALML3 | P27482 | 7/20 | 0.72 |
| ▸ | MAOA | P21397 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | SDHA | P31040 | 1/20 | 0.72 |
| ▸ | F10 | P00742 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829207 | 1.00 | MAOB (0.72) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL29822424 | 1.00 | MAOB (0.72) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL15793246 | 1.00 | MAOB (0.72) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL28109794 | 0.91 | CALML3 (0.65) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL16204405 | 0.89 | CALML3 (0.64) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL28109791 | 0.89 | CALML3 (0.64) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL12176864 | 0.89 | MAOB (0.70) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL28428084 | 0.89 | MAOB (0.58) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL28110345 | 0.89 | MAOB (0.58) | MAOBCALML3MAOALMNAPTGS1 | |
| SCHEMBL3575563 | 0.88 | CALML3 (0.59) | MAOBCALML3MAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106279054-A | Linezolid and the new preparation process of new intermediate thereof | 李药业有限公司 | 2017-01-04 | — | — | CN | claimed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | claimed |
| EP-2595968-B1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LTD (IN) | 2015-09-09 | — | — | EP | claimed |
| WO-2014045292-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LINEZOLID INTERMEDIATE | SYMED LABS LIMITED (IN) | 2014-03-27 | — | — | WO | claimed |
| US-20130324719-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LIMITED (IN) | 2013-12-05 | — | — | US | claimed |
| EP-2595968-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | Lee Pharma Limited (IN) | 2013-05-29 | — | — | EP | claimed |
| WO-2012114355-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LIMITED (IN) | 2012-08-30 | — | — | WO | claimed |
| US-11608320-B2 | Oxazolidinone hydroxamic acid derivatives | KUWAIT UNIVERSITY (KW) | 2023-03-21 | — | — | US | disclosed |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2022-08-25 | — | — | US | disclosed |
| CN-112409286-B | Synthesis method of N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | 杭州迪克科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-4001268-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | Hangzhou Dike Technologies Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
| EP-3932917-A2 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210238151-A1 | OXAZOLIDINONE HYDROXAMIC ACID DERIVATIVES | KUWAIT UNIVERSITY (KW) | 2021-08-05 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| EP-1121358-A1 | HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS | AstraZeneca AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000021960-A1 | HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | MAOB 1178/4885CALML3 4622/4885MAOA 1654/4885 |
| US-20130324719-A1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | HDAC1, HDAC3, HDAC6 | MAOB 1022/4885CALML3 2541/4885MAOA 891/4885 |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | CYP3A5, CYP1A2, CYP3A4 | MAOB 664/4885CALML3 1485/4885MAOA 638/4885 |
| US-20210238151-A1 | OXAZOLIDINONE HYDROXAMIC ACID DERIVATIVES | ALOX5, ALOX15, ALOX15B | MAOB 379/4885CALML3 3589/4885MAOA 254/4885 |
| US-11608320-B2 | Oxazolidinone hydroxamic acid derivatives | ALOX5, ALOX15, ALOX15B | MAOB 375/4885CALML3 3583/4885MAOA 251/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | MAOB 705/4885CALML3 4410/4885MAOA 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.